Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1079
- Registration Number
- NCT00963469
Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 907
- Registration Number
- NCT00963599
A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 829
- Registration Number
- NCT00960141
Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 77
- Registration Number
- NCT00953680
Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 36
- Registration Number
- NCT00945035
The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 13
- Registration Number
- NCT00943852
Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 190
- Registration Number
- NCT00943397
Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 256
- Registration Number
- NCT00943683
Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 384
- Registration Number
- NCT00920634
Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1664
- Registration Number
- NCT00920361